JP2022521895A5 - - Google Patents

Info

Publication number
JP2022521895A5
JP2022521895A5 JP2021547477A JP2021547477A JP2022521895A5 JP 2022521895 A5 JP2022521895 A5 JP 2022521895A5 JP 2021547477 A JP2021547477 A JP 2021547477A JP 2021547477 A JP2021547477 A JP 2021547477A JP 2022521895 A5 JP2022521895 A5 JP 2022521895A5
Authority
JP
Japan
Application number
JP2021547477A
Other languages
Japanese (ja)
Other versions
JP2022521895A (ja
JPWO2020168148A5 (https=
JP7465883B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018210 external-priority patent/WO2020168148A1/en
Publication of JP2022521895A publication Critical patent/JP2022521895A/ja
Publication of JPWO2020168148A5 publication Critical patent/JPWO2020168148A5/ja
Publication of JP2022521895A5 publication Critical patent/JP2022521895A5/ja
Application granted granted Critical
Publication of JP7465883B2 publication Critical patent/JP7465883B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547477A 2019-02-15 2020-02-14 ファルネソイドx受容体モジュレータとしての置換二環式化合物 Active JP7465883B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806042P 2019-02-15 2019-02-15
US62/806,042 2019-02-15
PCT/US2020/018210 WO2020168148A1 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators

Publications (4)

Publication Number Publication Date
JP2022521895A JP2022521895A (ja) 2022-04-13
JPWO2020168148A5 JPWO2020168148A5 (https=) 2022-12-20
JP2022521895A5 true JP2022521895A5 (https=) 2022-12-20
JP7465883B2 JP7465883B2 (ja) 2024-04-11

Family

ID=77745931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547477A Active JP7465883B2 (ja) 2019-02-15 2020-02-14 ファルネソイドx受容体モジュレータとしての置換二環式化合物

Country Status (7)

Country Link
US (1) US12227496B2 (https=)
EP (1) EP3924337A1 (https=)
JP (1) JP7465883B2 (https=)
KR (1) KR102905880B1 (https=)
CN (1) CN113677666A (https=)
CA (1) CA3129619A1 (https=)
IL (1) IL285570A (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240360265A1 (en) 2021-10-01 2024-10-31 Lg Chem, Ltd. Multiblock Copolymer, Resin Composition and Method for Preparing the Multiblock Copolymer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
WO1998017276A1 (en) 1996-10-25 1998-04-30 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
WO2004046162A2 (en) 2002-11-14 2004-06-03 The Scripps Research Institute Non-steroidal fxr agonists
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
WO2007076260A2 (en) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
EP2108017A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
MX2009013946A (es) 2007-07-02 2010-03-10 Glaxosmithkline Llc Agonistas del receptor de farnesoide x.
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
US20110230493A1 (en) 2008-11-21 2011-09-22 Pfizer Inc. 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
EP2454243A2 (en) 2009-07-15 2012-05-23 Merck Serono SA Tetrazole derivatives
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655368A1 (en) 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
IN2014DN09346A (https=) 2012-06-13 2015-07-17 Hoffmann La Roche
EP2903985A1 (en) 2012-10-03 2015-08-12 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
EP3116851B1 (en) 2014-03-13 2023-07-26 Salk Institute for Biological Studies Analogs of fexaramine and methods of making and using
WO2015172747A1 (en) 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
MX2017008057A (es) 2014-12-18 2017-09-28 Novartis Ag Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales.
EP3350164A4 (en) 2015-09-16 2019-03-27 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
US10703712B2 (en) * 2015-09-16 2020-07-07 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
WO2017049177A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017133521A1 (zh) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Fxr受体激动剂
ES2862194T3 (es) 2016-02-22 2021-10-07 Novartis Ag Métodos para usar agonistas del FXR
MX384205B (es) 2016-02-22 2025-03-14 Novartis Ag Metodos para usar agonistas de fxr.
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20200131129A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CA3055990A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7258763B2 (ja) 2017-03-15 2023-04-17 メタクリン,インク. ファルネソイドx受容体アゴニストおよびその使用
WO2018170167A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
PE20201170A1 (es) 2017-11-01 2020-10-28 Bristol Myers Squibb Co Compuestos biciclicos en puente como moduladores del receptor farnesoide x
WO2020061118A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EA202190661A1 (ru) 2018-09-18 2021-08-13 Метакрайн, Инк. Агонисты фарнезоидного х-рецептора для лечения заболевания
AR118050A1 (es) * 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
AU2020221371A1 (en) * 2019-02-15 2021-10-07 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators

Similar Documents

Publication Publication Date Title
JP2022521895A5 (https=)
JP2022519769A5 (https=)
CN305874930S (https=)
CN305800736S (https=)
CN305858352S (https=)
CN305858075S (https=)
CN305939060S (https=)
CN305935556S (https=)
CN305792680S (https=)
CN305793420S (https=)
CN305801969S (https=)
CN305793488S (https=)
CN305873202S (https=)
CN305798652S (https=)
CN305798357S (https=)
CN305934897S (https=)
CN305797987S (https=)
CN305797022S (https=)
CN305795658S (https=)
CN305934144S (https=)
CN305932332S (https=)
CN305928494S (https=)
CN305877511S (https=)
CN305875740S (https=)
CN305861108S (https=)